This federal contract IDV, awarded by the Defense Health Agency (DHA), provides a $2,500.00 delivery order to PPD Development LP, a global contract research organization (CRO), for military medical research and development services. The IDV is part of a larger $545 million contract that PPD Development LP holds with the National Institute of Allergy and Infectious Diseases (NIAID) for comprehensive and rapid response capabilities in research programs. PPD Development LP, a subsidiary of Thermo...
The National Institutes of Health National Institute of Allergy and Infectious Diseases awarded an Indefinite Delivery Contract to PPD Development LP with a potential value of $545,452,906 to provide comprehensive and rapid response capabilities for research programs through September 2028. Task orders issued against the contract include over $132 million for clinical trial management support services relating to COVID-19, as well as orders valued at $2.33 million, $2 million, and $82.5...
This is a multiple award Indefinite Delivery Contract (IDC) awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the Department of Health and Human Services, to provide comprehensive early phase clinical trial services. The $346.6 million contract, titled "Early Phase Clinical Trial Units (EPCTU)", facilitates Phase 0 through Phase II trials of investigational products against infectious diseases over a 10-year ordering period from...
The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases (NIAID) awarded a single-award Indefinite Delivery Indefinite Quantity (IDIQ) contract to Resourcepath, LLC, a certified Woman-Owned Small Business, to provide a comprehensive array of diagnostic pre-clinical services. The $12 million DIAGNOSTICS PRE-CLINICAL SERVICES PROGRAM IDIQ contract has a 7-year ordering period through June 2030. Under this contract, Resourcepath...
The National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a single-award indefinite delivery indefinite quantity contract to Cerba Research USA Inc. with a potential value of $5,000,000 to provide clinical central laboratory services in support of multi-center clinical trials. Two firm fixed price delivery orders have been issued against this contract to date, one for $529,892 for laboratory services in New York from 2023-2025, and another for $1,615,094 for...
This Indefinite Delivery Contract is a Multiple Award IDV under the In Vitro Assessments of Antimicrobial Activity master contract awarded by the National Institutes of Health National Institute of Allergy and Infectious Diseases. With a potential value of $30 million, it aims to procure services under Task Area A through January 2026 from List Biological Laboratories, Inc. The IDV seeks to obtain in vitro assessments of antimicrobial activity to support the agency's research efforts. This...
This is a single-award Indefinite Delivery Contract issued by the National Institutes of Health's National Institute of Allergy and Infectious Diseases (NIAID) to Advanced Bioscience Laboratories, Inc. (ABL), a foreign-owned for-profit organization that manufactures biologics. The Diagnostics Pre-Clinical Services Program IDIQ contract has a potential value of $24,000,000 over a 7-year ordering period ending June 2030. Under this contract, ABL will provide a broad range of preclinical diagnostic...
The National Institutes of Health's National Institute of Allergy and Infectious Diseases awarded multiple Indefinite Delivery/Indefinite Quantity contracts to provide preclinical development support for candidate products addressing HIV, HBV, HCV, and Mycobacterium tuberculosis. The total potential value of the IDV is $107,274,471 over seven years ending October 2027. Task orders have been issued under several areas. Lovelace Biomedical Research Institute received a $18,397 order to develop...
The National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a single award indefinite delivery contract to International Aids Vaccine Initiative Inc. to provide preclinical services supporting the development of biopharmaceutical therapeutics and diagnostics for infectious diseases. The potential value of the contract is $30 million with a performance period from January 2023 through September 2030. Services will be delivered under five task areas: product...
The National Institute of Allergy and Infectious Diseases awarded a single-award Indefinite Delivery Indefinite Quantity contract to Pharm-Olam, LLC with a potential value of $30,000,000.00 to provide preclinical services supporting the development of biopharmaceutical therapeutics and diagnostics for infectious diseases. Services will be performed across five task areas: product development planning and evaluation; analytical assay development and product characterization; process development...
This single-award IDV was issued by the Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases to provide centralized clinical laboratory services in support of clinical research trials. With a potential value of $5,000,000 and a period of performance through May 2026, the awardee PPD Development LP will deliver services including specimen handling, testing, data management, and clinical trial support.
The originating solicitation sought these services to enable evaluation of vaccines, diagnostics and therapeutics for infectious diseases through the Vaccine and Treatment Evaluation Units. Respondents were required to demonstrate facilities, equipment, expertise and management structure to perform clinical laboratory testing in compliance with regulations as outlined. The scope includes maintaining CLIA certification and providing supplies, courier and data transmission services, training and technical assistance for multi-site clinical research sponsored by the National Institute of Allergy and Infectious Diseases Division of Microbiology and Infectious Diseases.